Introduction

Interstitial lung diseases (ILDs) represent a heterogeneous group of over 200 lung disorders, characterized by inflammation and fibrosis of the interstitium. Despite their diversity, these conditions share common clinical, radiological, and histological features, making diagnosis and management challenging.

Etiology and Pathogenesis

ILDs can be idiopathic or secondary to systemic diseases, occupational exposures, drugs, or radiation. The pathogenesis often involves repeated cycles of lung injury and repair, leading to fibrosis. In idiopathic pulmonary fibrosis (IPF), the most common ILD, abnormal epithelial cells and myofibroblasts contribute to excessive extracellular matrix deposition.

Clinical Presentation and Diagnosis

Patients with ILDs typically present with progressive dyspnea and nonproductive cough. Physical examination may reveal inspiratory crackles and finger clubbing. High-resolution computed tomography (HRCT) is critical for diagnosis, often showing reticular abnormalities, ground-glass opacities, and honeycombing. Lung biopsy may be necessary in certain cases.

Treatment and Prognosis

Treatment of ILDs is largely dependent on the underlying cause. In idiopathic forms, management aims to slow disease progression and improve quality of life. Antifibrotic agents such as pirfenidone and nintedanib have shown efficacy in IPF. For ILDs secondary to connective tissue diseases, immunosuppressive therapy is often effective. Lung transplantation may be considered in severe cases. The prognosis varies widely, with IPF carrying a poor prognosis, and median survival of 2-5 years post-diagnosis.

Role of Healthcare Professionals

Healthcare professionals play a critical role in early detection, management, and monitoring of ILDs. Multidisciplinary collaboration involving pulmonologists, radiologists, pathologists, and rheumatologists is key to optimizing patient outcomes. Regular monitoring for disease progression and complications, such as pulmonary hypertension and lung cancer, is essential.

Conclusion

Despite advances in understanding ILDs, these diseases remain a significant cause of morbidity and mortality. Continued research into their pathogenesis and treatment, along with improved strategies for early detection and multidisciplinary care, are vital to improving patient outcomes.